WeChat: 13022869828
Phone: 86-29-89601602
E-mail: sales28@interlgroup.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China

Natural Lapatinib raw Materials Powder

< >

Product Overview:

lapatinib, trade name Tykerb, is an oral reversible small molecule tyrosine kinase inhibitor against HER-1/ HER-2. The mechanism of action of lapatinib is different from that of Herceptin, a humanized monoclonal antibody drug that has been approved for market. Lapatinib can down-regulate cell proliferation signal by double-blocking HER-1/ HER-2 pathway. The clinical indication is advanced or metastatic breast cancer with HER2 overexpression in combination with capecitabine and prior treatment with anthracycline, taxine, and trastuzumab. The effective rate of advanced first-line monotherapy is about 12-24%, and the general clinical guidelines recommend second-line drugs. The effective rate of combined treatment with capecitabine is about 26-33%, and the clinical benefit rate is up to 71.3%, which is also the most commonly used lapatinib combined chemotherapy regimen.

Booking Online

Free trial of samples

Natural Lapatinib raw Materials Powder Attributes

Lapatinib raw Materials Powder

CAS:231277-92-2

MF:C29H26ClFN4O4S

MW:581.06

EINECS:1806241-263-5

Specification: 99% min Lapatinib Powder

Sample:Lapatinib Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance:white

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Natural Lapatinib raw Materials Powder Details

Lapatinib Powder Usage and Synthesis.

Lapatinib (INN, Tykerb, Tyverb) is an oral active drug used in the form of lapatinib xylenesulfonate for the treatment of breast cancer and other solid tumors. It is a dual tyrosine kinase inhibitor that interrupts the HER2/neu and epidermal growth factor receptor pathways. It is used for the combination treatment of HER2-positive breast cancer. It is used to treat patients with advanced or metastatic breast cancer whose tumors overexpress HER.

Uses of Lapatinib.

Lapatinib is a new targeted treatment for breast cancer developed by GlaxoSmithKline, a tyrosine kinase inhibitor, which can effectively inhibit the activity of human epidermal growth factor receptor-1 (ErbB1) and human epidermal growth factor receptor-2 (ErbB2) tyrosine kinase. It is unique in that it can work through multiple pathways so that breast cancer cells do not receive the signals they need to grow, thereby inhibiting or killing tumor cells. At present, lapatinib is mainly used as a first-line treatment for trastuzumab resistant patients in China.

(1) Used in combination with capecitabine to treat ErbB-2 overexpression in patients with advanced or metastatic breast cancer who have previously been treated with anthracycline, paclitaxel, trastuzumab (Herceptin).

(2) Restrictions on use: Combination therapy must be used only after disease progression with trastuzumab.

(3) In combination with levotrozole for the treatment of hormone receptor-positive postmenopausal women with metastatic breast cancer that has been treated with hormone therapy and is overexpressed with HER2.

Lapatinib

Pharmacological action of Lapatinib.

Lapatinib toluenesulfonic acid tablet is a small molecule 4-aniline-quinazoline-like receptor tyrosine kinase inhibitor that inhibits epidermal growth factor receptor (ErbB1) and human epidermal factor receptor 2 (ErbB2). Among the four breast cancer cell lines, BT474 and SKBr3 were sensitive to lapatinib, with semi-inhibitory concentrations of 25 and 32nmol/L, while MDA-MB-468 and T47D cell lines were not sensitive, and the semi-inhibitory concentrations were in the micromolar level. RT112 (high expression of ErbB1 and ErbB2) and J82 (low expression of ErbB1 and ErbB2) enhance the efficacy of cisplatin. Epidermal factor-driven tumor growth was inhibited in a variety of animals. Lapatinib is effective against trastuzumab resistant tumor cell lines.

Lapatinib raw